Md. Ismail Hosen, Mahdi Sheikh, Maria I. Zvereva, Ghislaine Scélo et al.
BACKGROUND: Detecting pre-clinical bladder cancer (BC) using urinary biomarkers may provide a valuable opportunity for screening and management. Telomerase reverse transcriptase (TERT) promoter mutations detectable in urine have emerged as promising BC biomarkers. METHODS: We performed a nested case...
Md. Ismail Hosen, Nathalie Forey, Geoffroy Durand, Catherine Voegele et al.
Somatic mutations in the telomerase reverse transcriptase (TERT) promoter regions are frequent events in urothelial cancer (UC) and their detection in urine (supernatant cell-free DNA or DNA from exfoliated cells) could serve as putative non-invasive biomarkers for UC detection and monitoring. Howev...
Maria I. Zvereva, Eduard Pisarev, Md. Ismail Hosen, О. V. Kisil et al.
This review summarizes state-of-the-art knowledge in early-generation and novel urine biomarkers targeting the telomerase pathway for the detection and follow-up of bladder cancer (BC). The limitations of the assays detecting telomerase reactivation are discussed and the potential of transcription-a...
Hamid Pakmanesh, Seyed Omidreza Anvari, Nathalie Forey, Elisabete Weiderpass et al.
Bladder cancer (BC) is the 10th most common cancer in the world. While there are FDA-approved urinary assays to detect BC, none have demonstrated sufficient sensitivity and specificity to be integrated into clinical practice. Telomerase Reverse Transcriptase (TERT) gene mutations have been identifie...
Maria I. Zvereva, Md. Ismail Hosen, Nathalie Forey, Mahdi Sheikh et al.
Somatic mutations in the telomerase reverse transcriptase (TERT) promoter region are highly frequent in urothelial cancer (UC), and their detection in urine (cell-free DNA from the urine supernatant or DNA from exfoliated cells in the urine pellet) has demonstrated promising evidence as putative non...
Maria I. Zvereva, Eduard Pisarev, Md. Ismail Hosen, О. V. Kisil et al.
This review summarizes state-of-the-art knowledge in early-generation and novel urine biomarkers targeting the telomerase pathway for the detection and follow-up of bladder cancer (BC). The limitations of the assays detecting telomerase reactivation are discussed and the potential of transcription-a...